deltatrials
Completed PHASE3 NCT02181101

Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

Sponsor: AstraZeneca

Conditions Breast Neoplasms
Interventions FEC-Doc adjuvant chemotherapy FEC-DocGemzar adjuvant chemotherapy Zoledronic acid i.v. 2 years Zoledronic acid i.v. 5 years
Updated 5 times since 2017 Last updated: Jul 1, 2014 Started: Sep 30, 2005 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

Listed as NCT02181101, this PHASE3 trial focuses on Breast Neoplasms and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Chugai Pharma USA
  • Eli Lilly and Company
  • Janssen Diagnostics, LLC
  • Ludwig-Maximilians - University of Munich
  • Novartis
  • Sanofi
Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Munich, Germany